New hope for lung cancer patients who stopped responding to targeted therapy
NCT ID NCT06671379
First seen Mar 20, 2026 · Last updated May 22, 2026 · Updated 11 times
Summary
This study compares a new drug, SHR-A2009, with standard chemotherapy in about 500 adults with advanced EGFR-mutated non-small cell lung cancer that has worsened after EGFR-targeted treatment. The main goal is to see if SHR-A2009 delays cancer growth better than chemo. Participants must have measurable tumors and good overall health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.